Durlobactam

Durlobactam
Clinical data
Other names	ETX2514
Routes of; administration	Intravenous
Drug class	Antibacterial, beta-lactamase inhibitor
ATC code	None;
Legal status
Legal status	US: ℞-only co-packaged with sulbactam;
Identifiers
	IUPAC name [(2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl] hydrogen sulfate;
CAS Number	1467829-71-5;
PubChem CID	89851852;
DrugBank	DB16704; DBSALT003190;
ChemSpider	57617784; 71060725;
UNII	PSA33KO9WA; F78MDZ9CW9;
KEGG	D11591; D11592;
ChEMBL	ChEMBL4298137; ChEMBL4297378;
Chemical and physical data
Formula	C8H11N3O6S
Molar mass	277.25 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C[C@@H]2C[N@]([C@@H]1C(N)=O)C(=O)N2OS(O)(=O)=O;
	InChI InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6 /m1/s1; Key:BISPBXFUKNXOQY-RITPCOANSA-N;

Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter^[1] It is an analog of avibactam.

The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023.^[1]

References

^ ^a ^b "FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria". U.S. Food and Drug Administration (Press release). 24 May 2023. Retrieved 24 May 2023. This article incorporates text from this source, which is in the public domain.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.